Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DTwP-IPV vaccine
- Development stage
- Unknown
- Lead developer
- Intravacc
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The DTwP-IPV vaccine is a combination vaccine containing diphtheria toxoid, tetanus toxoid, whole-cell pertussis (wP) antigens, and inactivated poliovirus (IPV) components. Developed and produced by the National Institute for Public Health and the Environment (RIVM) in the Netherlands, it was historically used in the Dutch National Immunisation Programme (NIP) for infant primary vaccination. As a biologic vaccine, it targets the immune system to elicit protective antibody responses against *Bordetella pertussis* (whooping cough), *Corynebacterium diphtheriae* (diphtheria), *Clostridium tetani* (tetanus), and poliovirus. It has since been largely replaced in the Dutch NIP by acellular pertussis-containing combination vaccines (such as DTaP-IPV/Hib).
- Other names
- diphtheria-tetanus-whole cell pertussis-inactivated polio vaccineDTwP-IPV
02
Targets
NeuraminidaseTT (Tetanus toxoid)Diphtheria toxin
Beyond the preview
Go deeper on DTwP-IPV vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DTwP-IPV vaccine.